BPC-157 just got a pass from HHS. Here's what it covers and what it doesn't.

The short answer: yes, with conditions. On October 28, HHS said it won't take enforcement action against state-licensed pharmacies, federal facilities or licensed doctors that compound six peptides: BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax. It's one peptide per product, in set forms, with a prescription written for you. Research-use vendors aren't covered.

Status as of November 2, 2026: This is an interim enforcement policy, not FDA approval. None of the six is an FDA-approved drug. Nothing here is medical advice.

Key takeaways

Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.

An "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." In plain words: HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance" on its list (HHS notice, FR Doc. 2026-22192).

HHS gave its reason in the notice: "there is significant interest in the use of these peptides in compounding given the lack of availability of approved products," and the goal is "to expand and improve patient access." The policy holds while the FDA works through rulemaking on the official 503A bulks list, and it says future rulemaking "may propose adding some or all of these peptides" to that list.

I called this on October 20, eight days before it landed. The AP reported on October 15 that the "interim access policy" had gone to the White House, and that a formal listing would take years of rulemaking (AP via STAT, Oct 15, 2026).

Six peptides, each limited to certain routes. TB-500, MOTS-c and epitalon are injection only. KPV is oral or topical. Semax is nasal only. BPC-157 can be injected, taken by mouth or applied to the skin (Medical Daily, Oct 29, 2026; BakerHostetler, Oct 28, 2026).

No. The policy covers products with a single active ingredient, so a combo vial like the "Wolverine Stack" isn't covered (Medical Daily). What the research says about the two separately is in BPC-157 vs TB-500.

Regular compounding pharmacies, federal facilities and licensed physicians, working under section 503A, with a prescription written for a specific patient. The large 503B outsourcing facilities that compound in bulk aren't covered (BakerHostetler, Oct 28, 2026).

So in practice: a doctor would have to write it, and a 503A pharmacy would have to choose to make it. Whether one near you does is up to them.

No. This is a pass for pharmacies and doctors, not for the brand you order from now. Nothing in the notice changes how research-use-only products are treated. What that label does and doesn't mean is in what research use only really means.

I'll break down what changes once comments close and the FDA responds. Get it in your inbox.

No. The notice says it plainly: "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed." It also says the policy "does not establish any rights for any person and is not binding on HHS or the public," and HHS "may revisit" it if "a safety signal or product quality issue arises" (HHS notice).

Where each peptide stands in the FDA's longer process is in the compounding status tracker and the FDA panel vote on BPC-157 and KPV.

My take: it's never about your health. It's about who gets to make the money. Retatrutide is Lilly's drug, still in trials, and Lilly has sued eleven sellers over it since August. Reta has a drug company with patents and lawyers behind it. Most of these six don't. I think that's why nobody has chased them as hard. My guess is the pharmacy version ends up costing more and taking more hassle: a doctor visit, a prescription, one peptide per vial.

Comments go through regulations.gov on docket HHS-OASH-2026-0496. The notice says they can be submitted "until 2 weeks after date of publication in the Federal Register," and it was published October 30, which puts the deadline around November 13 (HHS notice; AJMC, Oct 29, 2026). Go to regulations.gov and search the docket number.

Would you switch from your vendor to a pharmacy with a prescription? Reply and tell me why or why not.

A licensed doctor can prescribe it and a state-licensed 503A pharmacy can compound it without FDA enforcement under the October 28 policy. It has to be BPC-157 alone, as an injection, oral or topical product, made for you specifically.

Yes, as an injection only, and only on its own. Blends with BPC-157 aren't covered.

Under the policy, a 503A pharmacy can compound Semax as a nasal product with a prescription. It's still not an FDA-approved drug.

No. It covers state-licensed pharmacies, federal facilities and licensed physicians under section 503A. Large 503B outsourcing facilities aren't included.

Yes. The notice says it isn't binding and HHS may revisit it if a safety signal or product quality issue comes up.

Want the one-page version of what's approved, legal and tested? Get the free BHN cheat sheet.